Navigation Links
ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
Date:11/25/2009

MOUNTAIN VIEW, Calif., Nov. 25 /PRNewswire/ -- ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The study demonstrated evidence of clinical efficacy in the reduction of disease severity as defined as a 70-point decrease in the Crohn's Disease Activity Index (CDAI) in patients treated with Traficet-EN over the course of 12 weeks; the more stringent measure of at least a 100-point decrease in the CDAI score was also met by week 12. In addition, Traficet-EN treatment benefited patients who had previously not responded to anti-TNF treatment. These results reported from the Induction phase of the PROTECT-1 trial, were presented today in a poster titled "PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B (TRAFICET-EN) in Crohn's Disease" by Satish Keshav, M.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University at the GASTRO 2009 United European Gastroenterology Federation and World Gastroenterology Organization (UEGW/WCOG) conference in London.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

Study Results

Results showed that the CDAI >/= 70-point response in patients with small bowel and/or colonic Crohn's disease treated with 500 mg once-daily dose (QD) of Traficet-EN for 12 weeks was
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 P&S ... with market overview, trends, DRO analysis, market ... recent developments, competitive scenario and top competitor ... Human Insulin Market Development and Demand Forecast ... Explore more about Global Human ...
(Date:7/28/2015)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... on Tuesday, August 4 at 11:30 a.m. Eastern Time ... report on pipeline and business progress.  ... 877-443-5662 or access the webcast at www.isispharm.com .  ... time at the same address. ABOUT ISIS ...
(Date:7/28/2015)... 2015   DigiPath Labs , the cannabis testing ... with True North Laboratory of Ann Arbor, ... leading global supplier of diagnostic solutions for food-borne pathogens, ... rapid diagnostic test kits to screen for food-borne ... "This joint effort is expected to result in the ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 3DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 2DigiPath Labs Partners with Romer Labs to Validate Food-Borne Pathogen and Mycotoxin Testing Solutions for Cannabis 3
... Germany, May 20 Miltenyi Biotec,announces the ... Beads. Myelin,is a specialized membrane which ensheathes ... nervous system. During preparation of single-cell,suspensions, myelin ... adult neural tissue, usually less than 5 ...
... that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... placebo in patients with Bipolar I Disorder. Results of ... medical meeting. Bipolar Disorder is a brain disorder ... and ability to function. It is often characterized by ...
Cached Medicine Technology:Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:7/28/2015)... ... July 28, 2015 , ... BMI of Texas, which ... the duodenal switch weight loss surgery procedure. Committed to helping patients achieve ... procedures, BMI of Texas is one of the first practices in South ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Kinetic Data announced that Schneider Electric has completed its upgrade and expansion ... a global organization with more than 170,000 employees in 134 countries supplying a ...
(Date:7/28/2015)... ... July 28, 2015 , ... A ... shipbreaking workers than they are in the general population. Surviving Mesothelioma has just ... now. , Researchers at Taiwan’s National Health Research Institutes and three Taiwanese ...
(Date:7/28/2015)... ... July 28, 2015 , ... Every summer, the public is reminded to ... when lighting fireworks in their own neighborhoods. Unfortunately, according to a recent report issued ... 2015 USA Today article " Eye Injuries Caused by Fireworks Doubled in Last 3 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Most employers have been using multi-tier ... Health Plan Survey shows a significant increase in the use of 4-tier plans, which ... copays -- a trend that is expected to continue, according to UBA. , UBA’s ...
Breaking Medicine News(10 mins):Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 2Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the "Company"), ... today announced that its Board of Directors has authorized ... public entity from July 31st to December 31st. The ... re-incorporation was completed and approved on February 16, 2009 ...
... Swiss Villa Dairy Farm in Lykens, Dauphin County, ... sales of raw milk on Feb. 24, Agriculture Secretary ... has not been pasteurized. Pennsylvania farms selling raw ... milk laboratory tested due to the health risks associated ...
... N.C., Feb. 24 Though the American Medical Association ... industry funding of CME and though some big pharma ... (one even eliminating funding for CME by third-party vendors), ... medical associations and teaching hospitals is funded by the ...
... XIFIN Inc., the leading provider of revenue ... it has added two new members to its ... rapid growth.(Logo: http://www.newscom.com/cgi-bin/prnh/20081013/LAM046LOGO )Steve Zaniboni joins ... most recently served as Chief Financial Officer of ...
... As we gear up for spring, the winter ... a reminder that emergency situations can occur without warning. ... emergencies, the American Public Health Association,s (APHA) "Get Ready: ... to update their emergency preparedness kits when they change ...
... higher incidence of lung cancer compared with those with the ... this risk, according to a study in the February 24 ... Institute. , Previous studies showed that individuals with a ... cancer. Some studies have also suggested that some of the ...
Cached Medicine News:Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2Health News:Educating the Market: Creating Value Through Support of Continuing Medical Education 2Health News:XIFIN Inc. Expands Its Executive Management Team 2Health News:Check Your Emergency Stocks When You Change Your Clocks, Says APHA 2Health News:Smoking behavior partially explains socioeconomic inequities in lung cancer incidence 2
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
... Central platform with integrated neck. ... platform utilizing an internal spring to ... use. Cutting Block fits into precision ... trephine blades sized 6.25 - 9.0mm. ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: